A genetically encoded BRET-based SARS-CoV-2 Mpro protease activity sensor

A genetically encoded BRET-based SARS-CoV-2 Mpro protease activity sensor

The main protease (Mpro) of SARS-CoV-2 is an important target for COVID-19 therapy. Here, a pair of genetically encoded BRET-based sensors for detecting Mpro activity are generated by sandwiching N-terminal autocleavage sites in between the mNeonGreen and NanoLuc proteins.

Bibliographic Details
Main Authors:	Anupriya M. Geethakumari, Wesam S. Ahmed, Saad Rasool, Asma Fatima, S. M. Nasir Uddin, Mustapha Aouida, Kabir H. Biswas
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-09-01
Series:	Communications Chemistry
Online Access:	https://doi.org/10.1038/s42004-022-00731-2

Similar Items

Protegrin-2, a potential inhibitor for targeting SARS-CoV-2 main protease Mpro
by: Zainab Jan, et al.
Published: (2023-01-01)

Structure-Based Virtual Screening and Functional Validation of Potential Hit Molecules Targeting the SARS-CoV-2 Main Protease
by: Balasubramanian Moovarkumudalvan, et al.
Published: (2022-11-01)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
by: Katarzyna Papaj, et al.
Published: (2022-01-01)

The temperature-dependent conformational ensemble of SARS-CoV-2 main protease (Mpro)
by: Ali Ebrahim, et al.
Published: (2022-09-01)

Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro)
by: Soumya Gulab Katre, et al.
Published: (2022-06-01)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease.
by: Katarzyna Papaj, et al.
Published: (2022-01-01)

In Silico Drug Repurposing of Penicillins to Target Main Protease Mpro of SARS-CoV-2
by: Baby Krishnaprasad, et al.
Published: (2020-11-01)

Statine-based peptidomimetic compounds as inhibitors for SARS-CoV-2 main protease (SARS-CoV‑2 Mpro)
by: Pedro Henrique R. de A. Azevedo, et al.
Published: (2024-04-01)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
by: Karen Anbro Gammeltoft, et al.
Published: (2023-09-01)

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
by: Qing Hu, et al.
Published: (2022-09-01)

In silico exploration of Lycoris alkaloids as potential inhibitors of SARS-CoV-2 main protease (Mpro)
by: Fredrick Mutie Musila, et al.
Published: (2022-09-01)

Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?
by: Matteo Pavan, et al.
Published: (2022-12-01)

Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease
by: János András Mótyán, et al.
Published: (2022-03-01)

Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design
by: Wei Yu, et al.
Published: (2021-12-01)

Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814
by: Haihai Jiang, et al.
Published: (2023-08-01)

In Silico Study of Secondary Metabolites in Dendrobium spp. as SARS-CoV-2 Antivirus on Main Protease (Mpro)
by: Anggiresti Kinasih, et al.
Published: (2022-03-01)

Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach
by: Ísis Venturi Biembengut, et al.

Molecular Dynamics Simulation of Ligands from Anredera cordifolia (Binahong) to the Main Protease (Mpro) of SARS-CoV-2
by: Jaka Fajar Fatriansyah, et al.
Published: (2022-01-01)

In silico prediction of inhibitory potential of a punicalagin β-anomer against SARS-COV-2 main protease (MPRO)
by: Norberto Monteiro, et al.
Published: (2023-01-01)

Theaflavin 3-gallate inhibits the main protease (Mpro) of SARS-CoV-2 and reduces its count in vitro
by: Mahima Chauhan, et al.
Published: (2022-07-01)

Erythromycin, retapamulin, pyridoxine, folic acid, and ivermectin inhibit cytopathic effect, papain-like protease, and MPRO enzymes of SARS-CoV-2
by: Shaibu Oricha Bello, et al.
Published: (2023-11-01)

Advances in the Development of SARS-CoV-2 Mpro Inhibitors
by: Laura Agost-Beltrán, et al.
Published: (2022-04-01)

In silico studies of selected xanthophylls as potential candidates against SARS-CoV-2 targeting main protease (Mpro) and papain-like protease (PLpro)
by: Karpiński Tomasz M., et al.
Published: (2021-06-01)

The Inhibitory Effect of Some Natural Bioactive D-Glucopyranoside Derivatives against SARS-CoV-2 Main Protease (Mpro) and Spike Protease (Spro)
by: Ajoy Kumer, et al.
Published: (2021-11-01)

Finding potential inhibitors for Main protease (Mpro) of SARS-CoV-2 through virtual screening and MD simulation studies
by: N. Anis Ahamed, et al.
Published: (2023-12-01)

Hemi-Babim and Fenoterol as Potential Inhibitors of MPro and Papain-like Protease against SARS-CoV-2: An In-Silico Study
by: Ahmad Alzamami, et al.
Published: (2022-04-01)

Fluorogenic in vitro activity assay for the main protease Mpro from SARS-CoV-2 and its adaptation to the identification of inhibitors
by: Julien Ihssen, et al.
Published: (2021-09-01)

Investigation of Thiocarbamates as Potential Inhibitors of the SARS-CoV-2 Mpro
by: Katarzyna Papaj, et al.
Published: (2021-11-01)

A Computational Study to Identify Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro) from Eucalyptus Active Compounds
by: Ibrahim Ahmad Muhammad, et al.
Published: (2020-09-01)

Computer-aided drug design for virtual-screening and active-predicting of main protease (Mpro) inhibitors against SARS-CoV-2
by: Renhui Dai, et al.
Published: (2023-11-01)

Genetic Surveillance of SARS-CoV-2 Mpro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
by: Jonathan T. Lee, et al.
Published: (2022-08-01)

Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies
by: Sakshi Piplani, et al.
Published: (2022-03-01)

Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 Mpro
by: Zhengyuan Wang, et al.
Published: (2021-06-01)

Mpropred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (Mpro) antagonists.
by: Nadim Ferdous, et al.
Published: (2023-01-01)

Identification of SARS-CoV-2 Main Protease (Mpro) Cleavage Sites Using Two-Dimensional Electrophoresis and In Silico Cleavage Site Prediction
by: Noémi Miltner, et al.
Published: (2023-02-01)

In-silico studies of Momordica charantia extracts as potential candidates against SARS-CoV-2 targeting human main protease enzyme (Mpro)
by: Ayodeji Adedayo, et al.
Published: (2023-01-01)

Identification of Potential Natural Bioactive Compounds from Glycyrrhiza glabra as Sars-CoV-2 Main Protease (MPRO) Inhibitors: In-Silico Approach
by: Ashraf A. A. Abdusalam, et al.
Published: (2022-06-01)

Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds
by: Io Antonopoulou, et al.
Published: (2022-01-01)

Identification of antiviral phytochemicals as a potential SARS-CoV-2 main protease (Mpro) inhibitor using docking and molecular dynamics simulations
by: Chirag N. Patel, et al.
Published: (2021-10-01)

Ratiometric BRET Measurements of ATP with a Genetically-Encoded Luminescent Sensor
by: Se-Hong Min, et al.
Published: (2019-08-01)